Contribute Try STAT+ Today

Top of the morning, to you, and a fine one it is. A delicious breeze and warm sun are combining to get the day off to a good start here on the Pharmalot campus, where one short person and one official mascot are both sleeping in. This leaves us to our usual laundry list of tasks, starting with brewing cups of stimulation to be followed by phone calls, lots of reading, and general foraging for items of interest. Speaking of which, here a few tidbits. Hope your day goes splendidly and you manage to keep cool. …

The Trump administration abandoned a proposal to ban many of the rebates that drug makers pay to pharmacy benefit managers under Medicare, STAT writes. The White House had argued eliminating rebates would prompt drug makers to lower list prices, but the proposal has been controversial since its unveiling in January. Drug companies had largely supported the idea, while PBMs and insurers were vocally opposed. Budget projections showed the rule could cost the federal government $177 billion in the next decade.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.